CIITA Protein

CIITA Protein

<div class="infobox infobox-protein">
| | |
|---|---|
| Protein Name | CIITA Protein |
| Gene | [CIITA](/genes/ciita) |
| UniProt ID | [P33076](https://www.uniprot.org/uniprot/P33076) |
| Alternative Names | Class II Major Histocompatibility Complex Transactivator, CIITA |
| Molecular Weight | ~125 kDa |
| Structure | N-terminal acidic domain, proline/serine/threonine-rich region, LRR repeat region |
| Subcellular Localization | Nucleus |
</div>

Overview

CIITA (Class II Major Histocompatibility Complex Transactivator) is a critical transcriptional coactivator that serves as the master regulator of MHC class II gene expression[@mach1996]. Originally characterized for its essential role in antigen presentation to CD4+ T cells, CIITA has emerged as an important player in neuroimmune interactions relevant to neurodegenerative diseases[@wistar2004].

Molecular Function

Transcriptional Coactivator Activity

CIITA does not directly bind DNA but functions as a transcriptional coactivator by recruiting chromatin remodelers and general transcription factors to MHC class II promoters. Its structure includes:

• N-terminal acidic domain: Mediates interactions with transcriptional coactivators like CBP/p300
• Proline/serine/threonine-rich region: Contains phosphorylation sites that regulate its activity
• Leucine-rich repeat (LRR) region: Involved in protein-protein interactions and nuclear localization

MHC Class II Regulation

...

CIITA Protein

<div class="infobox infobox-protein">
| | |
|---|---|
| Protein Name | CIITA Protein |
| Gene | [CIITA](/genes/ciita) |
| UniProt ID | [P33076](https://www.uniprot.org/uniprot/P33076) |
| Alternative Names | Class II Major Histocompatibility Complex Transactivator, CIITA |
| Molecular Weight | ~125 kDa |
| Structure | N-terminal acidic domain, proline/serine/threonine-rich region, LRR repeat region |
| Subcellular Localization | Nucleus |
</div>

Overview

CIITA (Class II Major Histocompatibility Complex Transactivator) is a critical transcriptional coactivator that serves as the master regulator of MHC class II gene expression[@mach1996]. Originally characterized for its essential role in antigen presentation to CD4+ T cells, CIITA has emerged as an important player in neuroimmune interactions relevant to neurodegenerative diseases[@wistar2004].

Molecular Function

Transcriptional Coactivator Activity

CIITA does not directly bind DNA but functions as a transcriptional coactivator by recruiting chromatin remodelers and general transcription factors to MHC class II promoters. Its structure includes:

• N-terminal acidic domain: Mediates interactions with transcriptional coactivators like CBP/p300
• Proline/serine/threonine-rich region: Contains phosphorylation sites that regulate its activity
• Leucine-rich repeat (LRR) region: Involved in protein-protein interactions and nuclear localization

MHC Class II Regulation

CIITA is essential for the expression of all MHC class II genes (HLA-DP, HLA-DQ, HLA-DR) by recruiting the transcriptional machinery including RFX5, RFXAP, and RFXANK to the promoters[@mach1996]. This function is critical for professional antigen-presenting cells (dendritic cells, B cells, macrophages).

Role in Neurodegenerative Diseases

Alzheimer's Disease

In Alzheimer's disease (AD), CIITA plays a complex role in neuroinflammation and immune responses:

Microglial Activation: CIITA expression in [microglia](/cell-types/microglia-neuroinflammation) regulates MHC class II presentation, influencing the inflammatory milieu around [amyloid-beta](/proteins/amyloid-beta) plaques[@wistar2004]. The chronic inflammatory response in AD involves dysregulated CIITA-mediated antigen presentation.

Adaptive Immunity: MHC class II expression on antigen-presenting cells in the brain enables presentation of neural antigens to infiltrating T cells, potentially modulating neuroinflammation[@michaelson2017].

Therapeutic Implications: Modulating CIITA activity represents a potential approach to fine-tune neuroinflammatory responses in AD, though this remains experimental.

Parkinson's Disease

In Parkinson's disease (PD), CIITA-mediated immune responses contribute to dopaminergic neuron degeneration:

[α-Synuclein](/proteins/alpha-synuclein) Immunity: CIITA regulates MHC class II expression on microglia that can present α-synuclein epitopes, potentially triggering adaptive immune responses[@sulzer2017].

Neuroinflammation: The progressive loss of dopaminergic [neurons](/entities/neurons) in the substantia nigra is accompanied by chronic neuroinflammation involving CIITA-expressing immune cells.

Therapeutic Targeting: Strategies targeting CIITA-mediated antigen presentation may modulate the neuroimmune axis in PD.

Amyotrophic Lateral Sclerosis

CIITA involvement in ALS includes:

T Cell-Mediated Immunity: In ALS, CIITA-regulated MHC class II expression influences the interaction between motor neurons and immune cells[@pagano2022].

Glial Cell Activation: [Astrocytes](/entities/astrocytes) and microglia expressing MHC class II via CIITA may contribute to motor neuron injury.

Neuroinflammation: The inflammatory environment in ALS involves CIITA-mediated antigen presentation pathways.

Signaling Pathways

CIITA integrates with several signaling pathways:

• IFN-γ Signaling: CIITA is strongly induced by interferon-gamma, which is elevated in neurodegenerative disease contexts[@wistar2004]
• JAK-STAT Pathway: STAT1 activation leads to CIITA transcription
• [NF-κB](/entities/nf-kb) Pathway: Cross-talk between CIITA and NF-κB signaling modulates inflammatory responses

Therapeutic Targeting

CIITA represents a potential therapeutic target for neurodegenerative diseases:

Immunomodulation: Modulating CIITA activity could fine-tune beneficial vs. harmful neuroinflammatory responses

Antigen Presentation: Targeting CIITA-mediated antigen presentation may reduce pathological immune activation

Combination Approaches: CIITA modulation could complement disease-modifying therapies

Research Directions

Key research areas include:

• Understanding cell-type specific CIITA regulation in the brain
• Developing small molecule modulators of CIITA activity
• Biomarker development based on CIITA expression patterns
• Clinical translation of neuroimmune modulation strategies

See Also

• [CIITA Gene](/genes/ciita)
• [MHC Class II](/genes/hladrb1)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)

External Links

• [UniProt: P33076](https://www.uniprot.org/uniprot/P33076)
• [PDB: CIITA Structure](https://www.rcsb.org/structure/6GBN)
• [GeneCards: CIITA](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CIITA)

References

[Unknown, Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annual Review of Immunology. 1996 (1996)](https://pubmed.ncbi.nlm.nih.gov/8717518/)

[Wistar R, et al., MHC class II expression in Alzheimer's disease brain. Journal of Neuroimmunology. 2004 (2004)](https://pubmed.ncbi.nlm.nih.gov/15589623/)

[Michaelson JS, et al., CIITA and adaptive immunity in neurodegeneration. Journal of Alzheimer's Disease. 2017 (2017)](https://pubmed.ncbi.nlm.nih.gov/28671194/)

[Sulzer D, et al., T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature. 2017 (2017)](https://pubmed.ncbi.nlm.nih.gov/28514433/)

[Pagano J, et al., Immune dysregulation in amyotrophic lateral sclerosis. Brain. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35036942/)